UBS Group
OBIO icon

UBS Group’s Orchestra BioMed OBIO Stock Holding History

UBS Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
325,773
+275,463
+548% +$1.13M ﹤0.01% 5427
2026
Q1 		$214K Buy
50,310
+38,921
+342% +$166K ﹤0.01% 6601
2025
Q4 		$47.3K Buy
11,389
+7,574
+199% +$30.6K ﹤0.01% 7248
2025
Q3 		$9.46K Sell
3,815
-22,324
-85% -$61.6K ﹤0.01% 8599
2025
Q2 		$70.1K Buy
26,139
+8,869
+51% +$25.9K ﹤0.01% 7512
2025
Q1 		$73.9K Sell
17,270
-6,795
-28% -$33.8K ﹤0.01% 7286
2024
Q4 		$96.3K Buy
24,065
+12,583
+110% +$67.6K ﹤0.01% 6900
2024
Q3 		$59K Buy
11,482
+4,328
+60% +$28.3K ﹤0.01% 6710
2024
Q2 		$58.3K Sell
7,154
-7,572
-51% -$43.9K ﹤0.01% 6575
2024
Q1 		$77.6K Buy
14,726
+1,294
+10% +$8.77K ﹤0.01% 6325
2023
Q4 		$123K Buy
13,432
+5,938
+79% +$40.5K ﹤0.01% 6063
2023
Q3 		$65.3K Buy
7,494
+79
+1% +$531 ﹤0.01% 6117
2023
Q2 		$51.9K Buy
+7,415
New +$112K ﹤0.01% 6454
2022
Q4 		– Sell
-2,824
Closed -$28K – 11013
2022
Q3 		$28K Buy
2,824
+2,327
+468% +$23.1K ﹤0.01% 6957
2022
Q2 		$5K Buy
497
+440
+772% +$4.37K ﹤0.01% 8908
2022
Q1 		$1K Buy
+57
New +$563 ﹤0.01% 9898
2021
Q4 		– Sell
-537
Closed -$5K – 10562
2021
Q3 		$5K Sell
537
-590
-52% -$5.82K ﹤0.01% 8547
2021
Q2 		$12K Buy
1,127
+249
+28% +$2.58K ﹤0.01% 7892
2021
Q1 		$10K Buy
878
+851
+3,152% +$10.4K ﹤0.01% 7933
2020
Q4 		$0 Buy
+27
New +$308 ﹤0.01% 8630

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

UBS Group's OBIO Position: Q2 2026 in Review

UBS Group increased its Orchestra BioMed (OBIO) stake by 548% in Q2 2026, buying an estimated $1.13M and bringing the position to 325,773 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #5427.

UBS Group first reported a position in OBIO in Q4 2020 and has held it in 20 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • UBS Group held 325,773 shares of Orchestra BioMed worth $1.41M as of Q2 2026.
  • UBS Group bought 275,463 Orchestra BioMed shares in Q2 2026, an estimated $1.13M.
  • Orchestra BioMed made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5427 holding.
  • UBS Group first reported a position in Orchestra BioMed in Q4 2020 and has held it in 20 quarters since.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.